Journal of Diabetes Research

Journal of Diabetes Research / 2009 / Article

Research Article | Open Access

Volume 2009 |Article ID 329632 | 12 pages |

Structural and Ultrastructural Analysis of Cerebral Cortex, Cerebellum, and Hypothalamus from Diabetic Rats

Academic Editor: Eva L. Feldman
Received28 Mar 2009
Accepted15 Jul 2009
Published01 Oct 2009


Autonomic and peripheral neuropathies are well-described complications in diabetes. Diabetes mellitus is also associated to central nervous system damage. This little-known complication is characterized by impairment of brain functions and electrophysiological changes associated with neurochemical and structural abnormalities. The purpose of this study was to investigate brain structural and ultrastructural changes in rats with streptozotocin-induced diabetes. Cerebral cortex, hypothalamus, and cerebellum were obtained from controls and 8 weeks diabetic rats. Light and electron microscope studies showed degenerative changes of neurons and glia, perivascular and mitochondrial swelling, disarrangement of myelin sheath, increased area of myelinated axons, presynaptic vesicle dispersion in swollen axonal boutoms, fragmentation of neurofilaments, and oligodendrocyte abnormalities. In addition, depressive mood was observed in diabetic animals. The brain morphological alterations observed in diabetic animals could be related to brain pathologic process leading to abnormal function, cellular death, and depressive behavioral.

1. Introduction

Besides autonomic and peripheral neuropathy, diabetes is also associated with gradually developing end-organ damage in the central nervous system [1]. This complication is referred as “diabetic encephalopathy” and characterized by impairment of cognitive functions and electrophysiological changes [2]. These functional changes are accompanied by structural and neurochemical abnormalities as well as by degenerative changes in the brain that could be related to chronically increased intracellular glucose concentration [35]. Several brain regions have been studied by biochemical and structural analysis in diabetes; however, few studies have been performed to determine the ultrastructural features of diabetes in cerebral cortex, hypothalamus, and cerebellum. These regions are involved in cognitive, motor, and neuroendocrine activities [69]; thus, their affectations during diabetes are relevant in the pathogenesis of the disease. This study was aimed to characterize the structural and ultrastructural brain changes in streptozotocin (STZ) induced diabetic rats.

2. Methods

2.1. Streptozotocin-Induced Diabetes

Male Sprague-Dawley rats weighing 100–150 g (Instituto Venezolano de Investigaciones Cientificas, IVIC) were used. Animals were housed, and food and water were provided ad libitum. Diabetes was induced by intravenous injection of streptozotocin (55 mg/kg in 0.2 M sodium citrate, pH 4.0; Sigma-Aldrich, St. Louis, MO, USA). Control rats ( ) were injected with vehicle. Diabetes was verified at weeks 1, 6, and 8 by measurement of tail blood glucose levels using a glucometer (Lifescan, Milpitas, CA, USA). Rats having a blood glucose level of 200 mg/dL were considered to be diabetic ( ). To prevent hypoglycemia, rats were allowed unlimited access to water with 2% glucose during 3 days after STZ injection. Subsequently, rats were allowed unlimited access to tap water. Urine glucose and ketoacids (assessed as acetoacetate) were evaluated using Multistix urinalysis strips (Bayer; Fisher Scientific, Germany). After 8 weeks, control and hyperglycemic rats were anesthetized by an intraperitoneal injection of tiobarbituric, and brain was perfused by intracardiac via using a 0.9% of saline solution containing 4% of glutaraldehyde. Thereafter, cerebrum and cerebellum were obtained for microscopy studies. Experimental procedures followed the ethical guidelines of the committee of bioethical and biosecurity of FONACIT (Caracas, Venezuela) and the committee of bioethical of Medical School (Universidad del Zulia, Maracaibo, Venezuela).

2.2. Light and Electron Microscopy

Pieces of selected brain regions (cerebral cortex, hypothalamus and cerebellum) were immediately placed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer, chopped to get pieces of approximately 1 mm2, and kept in the same glutaraldehyde solution for 12 hours at room temperature. Samples were postfixed in 1% osmium tetroxide for 1.5 hours, dehydrated in increasing concentrations of alcohol, immersed in propylene oxide, and embedded in Araldite 502 resin at . To confirm that hypothalamic area and all layers of cerebral and cerebellar samples were analyzed, thick tissue sections were made, stained with toluidine blue and analyzed by light microscopy. Ultrathin sections were placed on grids and stained with uranyl acetate and lead citrate. The thick sections were examined using a light microscope (Axioscop, Zeiss, Germany), and quantitative analysis of myelinated axonal transversal areas (cytoplasm areas) was performed using an IA32 system software (LECO Corporation, MI, USA); the grids with thin sections were examined in a transmission electron microscope (JEOL 1010, Akishima, Japan).

2.3. Quantification of Myelin and Mitochondrial Alterations

Randomly selected myelinated axons (100 per each cerebral cortex, hypothalamus or cerebellum areas) were counted and classified using an electron microscope. Abnormal myelin was arbitrarily defined on the basis of myelin disarrangement in type I: well-preserved myelin with local disarrangement of myelin sheath, type II: diffused local disarrangement of myelin sheath resembling a “collar” but preserving structural arrangement, and type III: collapsed myelin to form ovoid, diffused disarrangement, fusion or broken myelin sheath (Figure 1). Mitochondrial alterations were studied in randomly selected cellular body and neuropil areas (100 per each area) using an electron microscope. These organelles were counted and classified as vacuolated mitochondria (VM) and swollen mitochondria (SM) (Figure 2).

2.4. Apoptosis

To determine apoptosis a histological assay for selective labeling of cells with degraded DNA in tissue sections was used [10]. Apoptosis was determined using a commercial kit following the manufacturer’s indications (Promega, Madison, WI, USA). Areas of randomly selected tissues were analyzed and results were expressed as number of apoptotic nuclei per 0.065 mm2 of area. Apoptotic morphological features were also study by electron microscopy procedures.

2.5. Forced Swimming Test (FST) and Motor Activity

This test was performed with modifications of the Porsolt’s procedure [11] to determine the struggling time in control and diabetic rats. Briefly, FST was performed as follows: 8-week diabetic and control rats were placed individually in glass cylindrical tanks containing water ( ) at a depth of 30 cm. FST was performed daily for 15 days, and the struggling time was measured during 30-minute test. A rat was judged to be immobile when it remained floating in the water and made only small movements to keep its head above water. Struggle occurred when the rats were diving, jumping, strongly moving all four limbs, or scratching the walls. Animals were tested for motor activity in an optical digital animal activity monitor (Opto-Varimex-Minor, Columbus Instruments Co., Columbus OH, USA), which records motor activity values (pulses) automatically. Prior to the FST, the animals were placed for 5 minutes in the activity monitor where total horizontal activity and ambulatory and stereotypic movements were obtained.

2.6. Statistical Analysis

Data are expressed as mean SD. Statistical significance was determined by unpaired -test using Graph Pad InStat. Differences with values were considered statistically significant.

3. Results

3.1. Biochemical Parameters

STZ injection produced diabetic animals with consistent high levels of plasma glucose (Week 1: 409.13 92.55; Week 6: 363 77.92; Week 8: 306.4 84.66 mg/dL). Table 1 shows the biochemical parameters at week 8 when animals were sacrificed. Increased plasma glucose and urine glucose excretion were observed. At this time urine ketoacids were not detected. Decreased weight gain was observed in diabetic animal when compared to controls.

ParametersControl ( )Diabetes ( )

Blood glucose (mg/dL)127.5 21.8306.4 ± 84.6
Weight gain (g)287.9 39.2179.4 ± 8
Urine glucose +
Urine ketoacids

P < .05 versus control.
3.2. Light Microscopy Analysis

Analysis of toluidine-stained sections showed vacuolization of neurons, glia, as well as the neuropil in cerebral cortex, hypothalamus, and cerebellum of diabetic rats. Cellular vacuoles were mainly observed in pyramidal cells, Purkinje cells, and cells of cerebellar granulose and molecular layers. Cells with picnotic nuclei and condensed cytoplasm suggesting apoptotic cells were observed in normal and diabetic animals (Figure 3). Analysis of transversal sections of myelinated axons showed increased area in cerebral and cerebellar axons when compared to normal (Figure 4).

3.3. Apoptosis

Presence of apoptosis in light microscopy analysis was confirmed by TUNEL assay and by electron microscopy. Increased numbers of TUNEL positive cells were observed in cerebral cortex and cerebellum in diabetic animals when compared to controls, but they failed to reach a statistical significance. Electron microscopy study showed cells with condensed chromatin and cytoplasm in the brain parenchyma; some of these cells represent endothelial and perivascular cells (Figure 5).

3.4. Ultrastructural Analysis

Cerebral cortex, hypothalamus, and cerebellum showed ultrastructural features suggesting general swelling of neurons, glia, and neuropil. Cellular swelling was represented by local cytoplasm swelling, dilated rough endothelial reticulum (RER) fragments and swollen organelles mainly mitochondria, or by total cellular swelling (Figures 6, 7, and 8).

Vascular alterations were represented by endothelial cells showing local swelling areas or intense cellular swelling. In some instance, endothelial cell apoptosis was observed (Figure 9). Frequently, intense swelling of perivascular cells was observed in several blood vessels (Figure 9).

Mitochondrial abnormalities were observed in both cellular body and neuropil in the different regions. Increased vacuolated and swollen mitochondria in cerebral cortex, hypothalamus and cerebellum were observed in diabetic rats. No significant differences were observed when mitochondrial abnormalities in cellular body were compared with those in neuropil of diabetic animals. (Table 2 and Figure 2). Preserved mitochondria were frequently found besides altered mitochondria and, in some instance, myelin-like formations from degenerated mitochondria were observed (Figure 2).

ControlDiabetes values

Cellular body
V 2.1 2.425.7 9.81
S 4.73 1.9729.4 8.9
Total6.79 1.855.13 5.5
VM2.0 2.327.9 4.11
SM4.60 3.314.65 4.24
Total6.6 2.936.16 15.78

Cellular body
VM5.13 3.528.8 2.2
SM4.45 1.820.5 4.6
Total9.55 4.9749.32 5.79
VM3.3 2.834.3 1.74
SM1.68 1.7313.16 7.66
Total4.95 3.647.42 8.8

Cellular body
VM3.85 1.0629.35 12.31
SM3.83 3.0621.28 5.07
Total7.65 4.0650.61 8.24
VM6.03 2.2525.63 8.67
SM1.9 0.749.0 3.97
Total7.93 2.0234.64 11.84

VM: vacuolated mitochondria; SM: swollen mitochondria.

Axonal abnormalities were found in STZ-animals. Diabetic animals showed an elevated number of myelin alterations. Arbitrarily myelin alterations were classified as types I, II, and III according to the grade of myelin disarrangement (Figure 1). In general a low percentage of myelin alterations were observed in normal tissues. Tendency to increased myelin alterations was observed in cerebral cortex in diabetic rats, but only alteration of type III was statistically significant (Table 3). Elevated percentage of total types I, II, and III myelin alterations were observed in cerebellum and hypothalamus from diabetic animals (Table 3). Altered oligodendrocytes with local cytoplasm swelling, swollen organelles, and myelinated axons showing different types of myelin alterations were observed (Figure 10). Several both myelinated and unmyelinated axons showed fragmentation of neurofilaments (Figure 11). Synaptic boutons showed different grades of swelling with swollen mitochondria and dispersion of presynaptic vesicles (Figure 12).

Cerebral cortexControlDiabetes values

Alteration type
I4.33 3.109.56 2.98;NS
II2.17 1.574.72 3.36NS
III01.43 1.2
Total5.85 6.5715.74 5.51NS

Alteration type
I6.17 4.4813.68 11.5NS
II3.84 3.3733.12 10.32
III1.01 1.3635.51 20.28
Total11.02 4.5879.85 17.18

Alteration type
I8.06 2.0719.98 5.7
II2.68 2.2828.34 3.28
III011.51 4.21
Total10.75 4.1959.83 9.64

3.5. FST and Motor Activity

Diabetic rats showed depressive status. As shown in Table 4 diabetic animals had decreased struggle activity compared to controls when they were subjected to FST. Motor activity was also decreased in diabetes as observed in the lower number of movements and diminished ambulatory activity in diabetic animals.


Struggle time (seconds)27.36 11.4616.2 ± 6.1
Ambulatory activity (pulses)238.4 160.5113.25 ± 36.2
Number of movements (pulses)59.4 23.735.0 ± 15.5

versus control.

4. Discussion

Diabetic encephalopathy, characterized by impaired cognitive functions and neurochemical and structural abnormalities, may involve direct neuronal damage. This study assesses the effect of 8-week diabetic condition on the structure and ultrastructure of relevant regions of the rat brain. In general, all regions in this study presented morphologic alterations suggesting swelling of the brain. Increased area of myelinated axons in cerebral cortex and cerebellum and diverse degree of neuronal body swelling address this observation. In this regard, brain edema is the most common serious complication of diabetic ketoacidosis in children, where mechanisms of rapid changes in serum osmolality during therapy and others such as brain ischemia have been suggested [1215]. In these experiments, diabetic rats were not in ketoacidosis, and since they did not receive insulin, hyperglycemia could induce brain damage. Thus, hyperglycemia may cause brain acidosis and dehydration, both involved in diminished cerebral blood flow and ischemia [1618]. Ischemia-related edema involves stimulation of brain - - cotransporter system facilitating edema formation and swelling of endothelial cells [1924]. Thus, it is possible that those mechanisms contribute to the brain edema observed in this study; however, since lack of insulin may have consequences in terms of neuronal function, we cannot discard others inducers of brain alterations in diabetes. The ultrastructural lesions observed in this study are not considered to be a consequence of STZ, since a toxic effect of this compound on the central nervous system has been excluded [25].

Endothelial and perivascular edema observed in diabetic rats could induce an altered blood-brain barrier (BBB) function. Studies on animal models have shown that diabetes has deleterious effects on the BBB which may contribute to neurological complications associated to this condition [26]. Since perivascular pericytes, astrocytes, and adipocytes play an important role maintaining the function of the BBB [27, 28], perivascular swelling observed in diabetic rats could represent swollen pericytes, astrocytes, or adipocytes leading to disruption of the BBB functions.

Mitochondrial alterations were observed as other relevant finding in diabetic rats. An arbitrary classification of vacuolated mitochondria and swollen mitochondria in order to suggest different degrees of mitochondrial lesion was used in this study. In general, the percentage of mitochondria with vacuoles preserving the mitochondrial structure was higher than swollen mitochondria, suggesting progressive mitochondrial damage. Mitochondrial structural alterations have been related to oxidative stress. Previous reports have shown swelling of mitochondria during oxidative and nitrosative stress in diabetic STZ-rats [3, 29, 30]; this alteration was prevented by antioxidant treatment [29]. This mechanism may be related to vacuolated and swollen mitochondria observed in diabetic rat brain; however, it cannot be ruled out that the oxidative stress could be a consequence of a previous mitochondrial damage by increased intracellular glucose or by the effects of other damage inducers during diabetes. As interesting observation, unaltered mitochondria were often observed beside swollen or vacuolated mitochondria suggesting a selective mitochondrial resistant to the diabetic injury or a mitochondrial compensatory effect by increasing their number. These mitochondrial alterations could be accompanied by impairment mitochondrial function. In this regard, swollen hippocampal mitochondria from 4-week STZ rats downregulate GAP-43 and MKP-1 expressions; proteins relate to memory and cognition [30].

Diabetic peripheral neuropathy is the most common complication of diabetes; however, brain neuropathy has not been well studied. In this study, several grades of myelin alterations were observed in the different regions of the brain. Alteration type I could degenerate to wide myelin disarrangement (type III). These myelin abnormalities may be involved in a decreased propagation of nerve impulse and contribute to the brain disorders observed in diabetes. Several mechanisms have been suggested in myelin alterations in the brain of SZT–diabetic rats, such as decreased myelin-associated glycoprotein, autoantibodies to myelin basic protein, and myelin damage induced by nitric oxide [3, 3133].

It is expected, in myelin abnormalities and demyelination in the central nervous system, the oligodendrocyte remyelination [34]. In this regard, ultrastructural alterations of oligodendrocytes observed in this study suggest an impairment oligodendrocyte functions. Supporting this, STZ-induced diabetes hindered both oligodendrocyte and Schwann cell remyelination; hyperglycemia inhibits Schwann cell proliferation and restricts regeneration of axons [35] and RAGE expression on oligodendrocytes during experimental diabetes induces abnormal RAGE signaling with further cellular dysfunction [36]. It is possible that similar mechanisms are acting on oligodendrocytes in the central nervous system and may be related to the oligodendrocyte ultrastructural changes observed in this study.

Swollen axonal synaptic bouton with vacuolated and swollen mitochondria and high dispersion of synaptic vesicles was observed in the neuropil. These ultrastructural findings suggest an altered synaptic transmission and could contribute to abnormal synaptic plasticity and cognitive impairments observed in experimental diabetes [37, 38]. Dispersion of synaptic vesicles could be an early alteration, since similar findings have been reported in 9-day diabetic STZ- rats in the presynaptic hippocampal mossy fiber terminals [39]. In addition, alterations in axonal neurofilaments were also observed in this study. Several axons showed fragmentation of neurofilaments suggesting damage in the axonal transportation and impairment of neuron functions. Similarly, diabetic neurofilament alterations have been reported by others. In this regard, lack of insulin brain stimulation induces JNK hyperphosphorylation followed by hyperphosphorylation of tau and neurofilament damage showing as ultrastructural bunches [40]. In addition, neurofilaments can be GLcNAcylation/phosphorylation during diabetes leading to dysfunctional proteins [41].

As expected consequence of brain damage, necrosis, and/or apoptosis could take place during diabetic encephalopathy. In this study apoptosis was found increased in the different regions of the brain but did not reach significant statistic values, suggesting that diabetic encephalopathy could be related to necrosis and/or to dysfunctional disorders. Hyperglycemia observed in this study could induce cellular death by enhancing tissue acidosis [17].

Structural and ultrastructural brain changes were accompanied by depression in diabetic animals. Our results showed that diabetic animals had basal depressive behavior as shown by decreased struggle time and ambulatory activity. These data suggest that depression is involved in experimental diabetes and agree with the clinical depression observed in diabetic humans [42]. Cerebral cortex, cerebellum, and hypothalamus have been shown to be involved in depression. Cerebral metabolism abnormalities have been reported in patients with major and bipolar depression [43, 44]. Studies based on the hypothesis that metabolism impairment might be involved in the pathophysiology of depression, have shown that mitochondrial complexes I, III, and IV were inhibited only in cerebral cortex and cerebellum in chronic stress-induced depression in rats [45]. In addition, mitochondrial citrate synthase used as a marker of mitochondrial function has been reported decreased in depressed patients [46]. Thus, the mitochondrial ultrastructural alterations observed in cerebellum and cerebral cortex in this study could be involved in those functional alterations. In addition to functional impairment, cerebral cellular damage has been reported in experimental depression. In this regard, chronic stress/depression increases the vulnerability of neurons in the rat cerebral cortex by increasing caspase-3 positive neurons, suggesting apoptosis [47], a phenomenon observed in this study. The potential role of cerebellum in the pathophysiology of psychiatric disorders has also been reported. Structural and functional cerebellar abnormalities have been related to bipolar disorder, major depressive disorder and other psychiatric alterations [48, 49]. Structural and ultrastructural alterations in hypothalamus observed in this study could be related to depressive mood in rats. In this regard, dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis is frequently observed in human and experimental depression [50, 51].

In conclusion, our results support previous findings and add new information in the structural and ultrastructural alterations in the diabetic rat brain. Although it is difficult to extrapolate our findings to the human condition, the morphological alterations observed in this report may be one mechanism in the pathophysiology of depressive disorders.


This research was supported by Consejo Cientifico y Humanistico (CONDES, CC-1002-06). Universidad del Zulia, Maracaibo, Venezuela. The authors thank Dr. Jose Manuel Rodriguez for image analysis assistance.


  1. A. M. A. Brands, R. P. C. Kessels, E. H. F. De Haan et al., “Cerebral dysfunction in type I diabetes: effects of insulin, vascular risk factors and blood-glucose levels,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 159–168, 2004. View at: Google Scholar
  2. K. V. Allen, B. M. Frier, and M. W. J. Strachan, “The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 169–175, 2004. View at: Publisher Site | Google Scholar
  3. R. Mastrocola, F. Restivo, I. Vercellinatto et al., “Oxidative and nitrosative stress in brain mitochondria of diabetic rats,” Journal of Endocrinology, vol. 187, no. 1, pp. 37–44, 2005. View at: Publisher Site | Google Scholar
  4. A. L. McCall, “Cerebral glucose metabolism in diabetes mellitus,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 147–158, 2004. View at: Publisher Site | Google Scholar
  5. K. Weinger and A. M. Jacobson, “Cognitive impairment in patients with type 1 (insulin-dependent) diabetes mellitus: incidence, mechanisms and therapeutic implications,” CNS Drugs, vol. 9, no. 3, pp. 233–252, 1998. View at: Publisher Site | Google Scholar
  6. M. G. Dube, R. Torto, and S. P. Kalra, “Increased leptin expression selectively in the hypothalamus suppresses inflammatory markers CRP and IL-6 in leptin-deficient diabetic obese mice,” Peptides, vol. 29, no. 4, pp. 593–598, 2008. View at: Publisher Site | Google Scholar
  7. Q. Gao and T. L. Horvath, “Cross-talk between estrogen and leptin signaling in the hypothalamus,” American Journal of Physiology, vol. 294, no. 5, pp. E817–E826, 2008. View at: Publisher Site | Google Scholar
  8. K. Gerozissis, “Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies,” European Journal of Pharmacology, vol. 585, no. 1, pp. 38–49, 2008. View at: Publisher Site | Google Scholar
  9. D. Hu, H. Shen, and Z. Zhou, “Functional asymmetry in the cerebellum: a brief review,” Cerebellum, vol. 7, no. 3, pp. 304–313, 2008. View at: Publisher Site | Google Scholar
  10. Y. Gavrieli, Y. Sherman, and S. A. Ben-Sasson, “Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation,” Journal of Cell Biology, vol. 119, no. 3, pp. 493–501, 1992. View at: Publisher Site | Google Scholar
  11. R. D. Porsolt, M. Le Pichon, and M. Jalfre, “Depression: a new animal model sensitive to antidepressant treatments,” Nature, vol. 266, no. 5604, pp. 730–732, 1977. View at: Google Scholar
  12. J. A. Edge, M. Ford-Adams, and D. Dunger, “Causes of death in children with insulin dependent diabetes 1990–1996,” Archives of Disease in Childhood, vol. 81, no. 4, pp. 318–323, 1999. View at: Google Scholar
  13. J. A. Edge, “Cerebral oedema during treatment of diabetic ketoacidosis: are we any nearer finding a cause?” Diabetes Metabolism and Research Review, vol. 16, no. 5, pp. 316–324, 2000. View at: Google Scholar
  14. N. Glaser, P. Barnett, I. McCaslin et al., “Risk factors for cerebral edema in children with diabetic ketoacidosis,” The New England Journal of Medicine, vol. 344, no. 4, pp. 264–269, 2001. View at: Publisher Site | Google Scholar
  15. A. M. Glasgow, “Devastating cerebral edema in diabetic ketoacidosis before therapy,” Diabetes Care, vol. 14, no. 1, pp. 77–80, 1991. View at: Google Scholar
  16. D. Ding, S. I. Moskowitz, R. Li et al., “Acidosis induces necrosis and apoptosis of cultured hippocampal neurons,” Experimental Neurology, vol. 162, no. 1, pp. 1–12, 2000. View at: Publisher Site | Google Scholar
  17. P. A. Li, T. Kristián, M. Shamloo, and B. K. Siesjö, “Effects of preischemic hyperglycemia on brain damage incurred by rats subjected to 2.5 or 5 minutes of forebrain ischemia,” Stroke, vol. 27, no. 9, pp. 1592–1601, 1996. View at: Google Scholar
  18. N. Plesnila, J. Haberstok, J. Peters et al., “Effect of lactate acidosis on cell volume and intracellular pH of astrocytes,” Journal of Neurotrauma, vol. 16, no. 9, pp. 831–841, 1999. View at: Google Scholar
  19. M. E. O'Donnell, L. Tran, T. I. Lam et al., “Bumetanide inhibition of the blood-brain barrier Na-K-Cl cotransporter reduces edema formation in the rat middle cerebral artery occlusion model of stroke,” Journal of Cerebral Blood Flow and Metabolism, vol. 24, no. 9, pp. 1046–1056, 2004. View at: Publisher Site | Google Scholar
  20. G. Su, “Regulation of Na+-K+-Cl cotransporter in primary astrocytes by dibutyryl cAMP and high [K+]o,” American Journal of Physiology, vol. 279, no. 6, pp. C1710–C1721, 2000. View at: Google Scholar
  21. Y. Yan, R. J. Dempsey, A. Flemmer et al., “Inhibition of Na-K-Cl- cotransporter during focal cerebral ischemia decreases edema and neuronal damage,” Brain Research, vol. 961, no. 1, pp. 22–31, 2003. View at: Publisher Site | Google Scholar
  22. O. Kempski, S. V. Rosen, H. Weight et al., “Glial ion transport and volume control,” in Glial-Neuronal Interaction, N. J. Abbott, Ed., pp. 306–317, Academy of Sciences, New York, NY, USA, 1991. View at: Google Scholar
  23. C. Iadecola, “Mechanisms of cerebral ischemic damage,” in Cerebral Ischemia: Molecular and Cellular Pathophysiology, W. Walz, Ed., pp. 3–34, Humana Press, Totowa, NJ, USA, 1999. View at: Google Scholar
  24. C. M. Isales, L. Min, and W. H. Hoffman, “Acetoacetate and β-hydroxybutyrate differentially regulate endothelin-1 and vascular endothelial growth factor in mouse brain microvascular endothelial cells,” Journal of Diabetes and Its Complications, vol. 13, no. 2, pp. 91–97, 1999. View at: Publisher Site | Google Scholar
  25. S. S. W. Tay and W. C. Wong, “Gracile nucleus of streptozotocin-induced diabetic rats,” Journal of Neurocytology, vol. 20, no. 5, pp. 356–364, 1991. View at: Google Scholar
  26. B. T. Hawkins and R. D. Egleton, “Pathophysiology of the blood-brain barrier: animal models and methods,” Current Topics in Developmental Biology, vol. 80, pp. 277–309, 2007. View at: Publisher Site | Google Scholar
  27. T. J. Guzik, P. J. Marvar, M. Czesnikiewicz-Guzik et al., “Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction,” Journal of Physiology and Pharmacology, vol. 58, no. 4, pp. 591–610, 2007. View at: Google Scholar
  28. J. Xu and E. A. Ling, “Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers,” Journal of Anatomy, vol. 184, no. 2, pp. 227–237, 1994. View at: Google Scholar
  29. C. Bonnard, A. Durand, S. Peyrol et al., “Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice,” The Journal of Clinical Investigation, vol. 118, no. 2, pp. 789–800, 2008. View at: Publisher Site | Google Scholar
  30. J. Zhou, L. Wang, S. Ling et al., “Expression changes of growth-associated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats,” Experimental Neurology, vol. 206, no. 2, pp. 201–208, 2007. View at: Google Scholar
  31. R. Kawashima, H. Kojima, K. Nakamura et al., “Alterations in mRNA expression of myelin proteins in the sciatic nerves and brains of streptozotocin-induced diabetic rats,” Neurochemical Research, vol. 32, no. 6, pp. 1002–1010, 2007. View at: Publisher Site | Google Scholar
  32. L. E. Teplinskaia, N. E. Iastrebova, I. D. Vetrov et al., “Immunologic autoagression in patients with diabetic retinopathy under type I diabetes mellitus,” Zhurnal Mikrobiologii Epidemiologii Immunobiologii, no. 7, pp. 59–62, 2006. View at: Google Scholar
  33. D. W. Zochodne and D. Levy, “Nitric oxide in damage, disease and repair of the peripheral nervous system,” Cellular and Molecular Biology, vol. 51, no. 3, pp. 255–267, 2005. View at: Google Scholar
  34. E. F. Bondan, M. A. Lallo, A. H. Trigueiro et al., “Delayed Schwann cell and oligodendrocyte remyelination after ethidium bromide injection in the brainstem of Wistar rats submitted to streptozotocin diabetogenic treatment,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 5, pp. 637–646, 2006. View at: Publisher Site | Google Scholar
  35. L. F. Gumy, E. T. W. Bampton, and A. M. Tolkovsky, “Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG,” Molecular and Cellular Neuroscience, vol. 37, no. 2, pp. 298–311, 2008. View at: Publisher Site | Google Scholar
  36. C. Toth, A. M. Schmidt, U. I. Tuor et al., “Diabetes, leukoencephalopathy and rage,” Neurobiology of Disease, vol. 23, no. 2, pp. 445–461, 2006. View at: Publisher Site | Google Scholar
  37. C. A. Grillo, G. G. Piroli, G. E. Wood et al., “Immunocytochemical analysis of synaptic proteins provides new insights into diabetes-mediated plasticity in the rat hippocampus,” Neuroscience, vol. 136, no. 2, pp. 477–486, 2005. View at: Publisher Site | Google Scholar
  38. A. Artola, “Diabetes-, stress- and ageing-related changes in synaptic plasticity in hippocampus and neocortex—the same metaplastic process?” European Journal of Pharmacology, vol. 585, no. 1, pp. 153–162, 2008. View at: Google Scholar
  39. A. M. Magariños and B. S. McEwen, “Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 11056–11061, 2000. View at: Google Scholar
  40. R. Schechter, D. Beju, and K. E. Miller, “The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 979–986, 2005. View at: Publisher Site | Google Scholar
  41. W. B. Dias and G. W. Hart, “O-GlcNAc modification in diabetes and Alzheimer's disease,” Molecular BioSystems, vol. 3, no. 11, pp. 766–772, 2007. View at: Publisher Site | Google Scholar
  42. R. J. Anderson, K. E. Freedland, R. E. Clouse, and P. J. Lustman, “The prevalence of comorbid depression in adults with diabetes: a meta-analysis,” Diabetes Care, vol. 24, no. 6, pp. 1069–1078, 2001. View at: Google Scholar
  43. L. Mah, C. A. Zarate Jr., J. Singh et al., “Regional cerebral glucose metabolic abnormalities in bipolar II depression,” Biological Psychiatry, vol. 61, no. 6, pp. 765–775, 2007. View at: Publisher Site | Google Scholar
  44. S. H. Song, I. J. Kim, S. J. Kim et al., “Cerebral glucose metabolism abnormalities in patients with major depressive symptoms in pre-dialytic chronic kidney disease: statistical parametric mapping analysis of F-18-FDG PET, a preliminary study,” Psychiatry and Clinical Neurosciences, vol. 62, no. 5, pp. 554–561, 2008. View at: Publisher Site | Google Scholar
  45. G. T. Rezin, M. R. Cardoso, C. L. Gonçalves et al., “Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression,” Neurochemistry International, vol. 53, no. 6–8, pp. 395–400, 2008. View at: Publisher Site | Google Scholar
  46. A. Gardner, D. Salmaso, D. Nardo et al., “Mitochondrial function is related to alterations at brain SPECT in depressed patients,” CNS Spectrums, vol. 13, no. 9, pp. 805–814, 2008. View at: Google Scholar
  47. A. Bachis, M. I. Cruz, R. L. Nosheny et al., “Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex,” Neuroscience Letters, vol. 442, no. 2, pp. 104–108, 2008. View at: Publisher Site | Google Scholar
  48. L. Baldaçara, J. G. F. Borgio, A. L. T. de Lacerda et al., “Cerebellum and psychiatric disorders,” Revista Brasileira de Psiquiatria, vol. 30, no. 3, pp. 281–289, 2008. View at: Publisher Site | Google Scholar
  49. P. B. Fitzgerald, A. R. Laird, J. Maller et al., “A meta-analytic study of changes in brain activation in depression,” Human Brain Mapping, vol. 29, no. 6, pp. 683–695, 2008. View at: Publisher Site | Google Scholar
  50. K. Mizoguchi, H. Shoji, R. Ikeda et al., “Persistent depressive state after chronic stress in rats is accompanied by HPA axis dysregulation and reduced prefrontal dopaminergic neurotransmission,” Pharmacology Biochemistry and Behavior, vol. 91, no. 1, pp. 170–175, 2008. View at: Publisher Site | Google Scholar
  51. D. F. Swaab, A. M. Bao, and P. J. Lucassen, “The stress system in the human brain in depression and neurodegeneration,” Ageing Research Reviews, vol. 4, no. 2, pp. 141–194, 2005. View at: Publisher Site | Google Scholar

Copyright © 2009 Juan P. Hernández-Fonseca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

3062 Views | 1658 Downloads | 61 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.